Aaron Kantoff, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, indicates that Kantoff does not beneficially own any non-derivative or derivative securities of the company. The filing is a routine disclosure required by the Securities Exchange Act of 1934 and the Investment Company Act of 1940, which mandates insiders to report their securities holdings in the company. The address listed for Kantoff is c/o Avalo Therapeutics, Inc. at 540 Gaither Road, Suite 400, Rockville, MD, 20850.

Aaron Kantoff, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, indicates that Kantoff does not beneficially own any non-derivative or derivative securities of the company. The filing is a routine disclosure required by the Securities Exchange Act of 1934 and the Investment Company Act of 1940, which mandates insiders to report their securities holdings in the company. The address listed for Kantoff is c/o Avalo Therapeutics, Inc. at 540 Gaither Road, Suite 400, Rockville, MD, 20850.